87789-61-5

Basic information

• Product Name: 5-Benzyloxy-2-(1-piperazinyl)pyriMidine
• Synonyms: 5-Benzyloxy-2-(1-piperazinyl)pyriMidine;5-(PhenylMethoxy)-2-(1-piperazinyl)-pyriMidine;5-(Benzyloxy)-2-(piperazin-1-yl)pyriMidine
• CAS NO: 87789-61-5
• Molecular Formula: C₁₅H₁₈N₄O
• Molecular Weight: 270
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 87789-61-5.mol
• Article Data: 5

Chemical Properties

• Melting Point: 95-96 °C
• Boiling Point: 469.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.181±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 8.57±0.10(Predicted)
• CAS DataBase Reference: 5-Benzyloxy-2-(1-piperazinyl)pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Benzyloxy-2-(1-piperazinyl)pyriMidine(87789-61-5)
• EPA Substance Registry System: 5-Benzyloxy-2-(1-piperazinyl)pyriMidine(87789-61-5)

Safety Data

• Hazardous Substances Data: 87789-61-5(Hazardous Substances Data)

Usage

Description

5-Benzyloxy-2-(1-piperazinyl)pyriMidine is a chemical compound that serves as an intermediate in the synthesis of various central nervous system (CNS) agents. It is characterized by its unique molecular structure, which includes a benzyloxy group at the 5-position and a piperazinyl group at the 2-position of the pyrimidine ring. 5-Benzyloxy-2-(1-piperazinyl)pyriMidine plays a crucial role in the development of pharmaceuticals targeting the CNS.

Uses

Used in Pharmaceutical Industry:
5-Benzyloxy-2-(1-piperazinyl)pyriMidine is used as a key intermediate in the synthesis of CNS agents for the treatment of various neurological and psychiatric disorders. Its unique structure allows for the development of compounds with specific binding affinities and selectivity for target receptors in the central nervous system, leading to potential therapeutic benefits.
As an intermediate in the preparation of CNS agents, 5-Benzyloxy-2-(1-piperazinyl)pyriMidine contributes to the advancement of pharmaceutical research and development. Its role in the synthesis of these agents is essential for creating effective treatments for a range of CNS-related conditions, ultimately improving the quality of life for patients suffering from these disorders.

InChI:InChI=1S/C15H18N4O/c1-2-4-13(5-3-1)12-20-14-10-17-15(18-11-14)19-8-6-16-7-9-19/h1-5,10-11,16H,6-9,12H2

Upstream product

• 110-85-0 piperazine 
• 138274-14-3 5-(benzyloxy)-2-chloropyrimidine 
• 100-39-0 benzyl bromide 
• 99931-82-5 1-(5-bromopyrimidin-2-yl)piperazine 
• 100-51-6 benzyl alcohol 

Downstream Products

• 106644-77-3 (1R*,2S*,3R*,4S*)-N-<4-<4-(5-Benzyloxy-2-pyrimidinyl)-1-piperazinyl>butyl>-2,3-bicyclo<2.2.1>heptanedicarboximide 
• 1333320-39-0 N-{2-[4-(5-benzyloxy-pyrimidin-2-yl)-piperazin-1-yl]-2-oxo-ethyl}-2-fluoropyridine-4-carboxamide 
• 1333320-40-3 [⁽¹⁸⁾F]-N-{2-[4-(5-benzyloxy-pyrimidin-2-yl)-piperazin-1-yl]-2-oxo-ethyl}-2-fluoropyridine-4-carboxamide 
• 1333316-46-3 N-{2-[4-(5-benzyloxy-pyrimidin-2-yl)-piperazin-1-yl]-2-oxo-ethyl}-2-iodopyridine-4-carboxamide 
• 1333316-49-6 tert-butyl (2-{4-[5-(benzyloxy)pyrimidin-2-yl]piperazin-1-yl}-2-oxoethyl)carbamate 

Relevant articles and documents

SPECT IMAGING AGENTS OF AMYLOID PLAQUES

The invention relates to novel iodine -radiolabeled compounds useful for diagnosing Alzheimer's desease, to respective novel precursors for the synthesis of such compounds, and to the process of manufacturing said imaging agent of the following Formula (I), wherein Q is a six membered aromatic ring, either carbocycle or heterocycle with one N- atom, wherein X1, X2, X3, X4 and X5 are independently selected from N or C, and wherein zero or one of X1 ( X2, X3, X4 or X5 is N and the remaining ones are C; A is either Sn(alkyl)3, I, l-123, l-124, l-125, l-131, Br; wherein alkyl comprises methyl, ethyl, propyl, butyl, pentyl and hexyl, Y is C or N; with the proviso that if X1 ( X2, X3, X4 or X5 has the meaning of N, substitution by A in that position is excluded; or a pharmaceutically acceptable salt thereof.

Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*,2S*3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3-b icyclo[2.2.1]heptanedicarboxime (Tandospirone) and related compounds

A series of cyclic imides bearing a ω-(4-aryl and 4-heteroaryl-1-piperazinyl)alkyl moieties was synthesized and tested in vivo for anxiolytic activity. The in vitro binding affinities of these compounds were also examined for 5-HT(1A) receptor sites. Structure-activity relationships within these series are discussed. One of these compounds, (1R*,2S*,3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3- bicyclo[2.2.1]heptanedicarboximide (1: tandospirone), was found to be equipotent with buspirone in its anxiolytic activity and more anxio-selective than buspirone and diazepam. Tandospirone (1) is currently undergoing clinical evaluation as a selective anxiolytic agent.

2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines

1-[4-(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]piperazines with 2-pyrimidyl substituents in the 4- position have been synthesized and demonstrate useful anxiolytic properties. The compound 4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione, which has selective anxiolytic activity, constitutes the preferred embodiment of the invention.